It’s tough to underestimate the success of Novo Nordisk, the corporate behind “miracle” weight reduction jab Wegovy.
Such is the recognition of the revolutionary weekly urge for food suppressant lauded by Elon Musk and Kim Kardashian that the corporate has change into essentially the most precious in Europe.
The corporate additionally produces Ozempic, a carefully linked diabetes therapy that may be prescribed as a weight reduction therapy.
Novo Nordisk’s income jumped by 1 / 4 final 12 months to 175 billion Danish krone ($A39bn) pushed largely by gross sales of Wegovy.
Denmark’s nationwide financial institution has stated that if it weren’t for the fortunes of Novo Nordisk, the nation could be in recession.
The corporate is price nearly $A670bn and is now extra precious than your complete Danish economic system mixed.
Novo Nordisk was based by Nobel-winning physiologist August Krogh and was the primary firm to promote insulin in Scandinavia.
It made a profitable enterprise supplying insulin however its current fortunes are right down to Wegovy which has been discovered to assist sufferers lose as much as 12 per cent of their physique weight.
It really works by mimicking a intestine hormone that methods the mind into feeling full.
“There are different massive firms in Denmark and they’re additionally essential however we now have not had one thing as massive as this and we now have not had one thing rising as quick as this,” Las Olsen, chief economist at Danske Financial institution, informed Britain’s Every day Telegraph.
“Novo Nordisk is by far the most important taxpayer in Denmark and that’s solely growing.
“For the final 12 months, if it hadn’t been for this progress, truly there would have been a contraction in Danish GDP.”
